Best Practice & Research Clinical Haematology最新文献_第6页

The role of registries in hematological disorders 登记册在血液病中的作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-06-01 DOI: 10.1016/j.beha.2024.101556

Helen Baldomero , Daniel Neumann , Nada Hamad , Yoshiko Atsuta , Anna Sureda , Minako Iida , Amado Karduss , Alaa M. Elhaddad , Nosa G. Bazuaye , Carmem Bonfim , Rafael de la Camara , Naeem A. Chaudhri , Fabio Ciceri , Cinthya Correa , Cristobal Frutos , Sebastian Galeano , Laurent Garderet , Raffaella Greco , Gregorio Jaimovich , Yoshihisa Kodera , Dietger Niederwieser

{"title":"The role of registries in hematological disorders","authors":"Helen Baldomero , Daniel Neumann , Nada Hamad , Yoshiko Atsuta , Anna Sureda , Minako Iida , Amado Karduss , Alaa M. Elhaddad , Nosa G. Bazuaye , Carmem Bonfim , Rafael de la Camara , Naeem A. Chaudhri , Fabio Ciceri , Cinthya Correa , Cristobal Frutos , Sebastian Galeano , Laurent Garderet , Raffaella Greco , Gregorio Jaimovich , Yoshihisa Kodera , Dietger Niederwieser","doi":"10.1016/j.beha.2024.101556","DOIUrl":"10.1016/j.beha.2024.101556","url":null,"abstract":"<div><p>Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system with a healthy one (allogeneic HCT). Decades later, the procedure was adapted to apply maximal chemotherapy or radiotherapy, which would result in bone marrow failure, but could be remedied by an infusion of a patient's own cryopreserved bone marrow (autologous HCT). Both treatments are high-risk and complex, especially during the initial phases. However, concerted efforts, vision, and collaboration between physicians and centers worldwide have resulted in HCT becoming a standard of care for many hematological disorders with progressive improvements in outcomes. Registries and the collaboration of societies worldwide have enabled the delivery of this curative therapy to many patients with fatal hematological diseases. More than 1.5 million HCT were performed between 1957 and 2019, and activity is continuously increasing worldwide.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 2","pages":"Article 101556"},"PeriodicalIF":2.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141732112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation 预测、监测或控制同种异体造血细胞移植后 GvL 和 GvHD 的主要组织相容性抗原

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-05-15 DOI: 10.1016/j.beha.2024.101555

Kyra J. Fuchs, J.H. Frederik Falkenburg, Marieke Griffioen

{"title":"Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation","authors":"Kyra J. Fuchs, J.H. Frederik Falkenburg, Marieke Griffioen","doi":"10.1016/j.beha.2024.101555","DOIUrl":"10.1016/j.beha.2024.101555","url":null,"abstract":"<div><p>Allogeneic hematopoietic cell transplantation (alloHCT) provides a potential curative treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) effect is induced by donor T cells attacking patient hematopoietic (malignant) cells. However, if healthy non-hematopoietic tissues are targeted, Graft-versus-Disease (GvHD) may develop. After HLA-matched alloHCT, GvL and GvHD are induced by donor T cells recognizing polymorphic peptides presented by HLA on patient cells, so-called minor histocompatibility antigens (MiHAs). The balance between GvL and GvHD depends on the tissue distribution of MiHAs and T-cell frequencies targeting these MiHAs. T cells against broadly expressed MiHAs induce GvL and GvHD, whereas those targeting MiHAs with hematopoietic-restricted expression induce GvL without GvHD. Recently, the MiHA repertoire identified in natural immune responses after alloHCT was expanded to 159 total HLA-I-restricted MiHAs, including 14 hematopoietic-restricted MiHAs. This review explores their potential relevance to predict, monitor, and manipulate GvL and GvHD for improving clinical outcome after HLA-matched alloHCT.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 2","pages":"Article 101555"},"PeriodicalIF":2.1,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000215/pdfft?md5=4151fa3924ab77b95bb5f58ae2a5d38a&pid=1-s2.0-S1521692624000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141061962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “HIV-associated lymphoma” [Best Pract Res Clin Haematol 25 (2012) 101–117] 对 "艾滋病毒相关淋巴瘤 "的更正 [Best Pract Res Clin Haematol 25 (2012) 101-117]

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-04-30 DOI: 10.1016/j.beha.2024.101554

Lawrence D. Kaplan

引用次数: 0

Cytogenetics in haematology 血液学中的细胞遗传学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-04-10 DOI: 10.1016/j.beha.2024.101553

Yanming Zhang, Brigitte Schlegelberger

引用次数: 0

Cytogenetics and genomics in CML and other myeloproliferative neoplasms CML 和其他骨髓增生性肿瘤的细胞遗传学和基因组学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-04-03 DOI: 10.1016/j.beha.2024.101552

Hans H. Kreipe , Brigitte Schlegelberger

{"title":"Cytogenetics and genomics in CML and other myeloproliferative neoplasms","authors":"Hans H. Kreipe , Brigitte Schlegelberger","doi":"10.1016/j.beha.2024.101552","DOIUrl":"https://doi.org/10.1016/j.beha.2024.101552","url":null,"abstract":"<div><p>Chronic myeloid leukemia is defined by the presence of the Philadelphia translocation t (9; 22) resulting in the <em>BCR::ABL1</em> fusion. The other myeloproliferative neoplasms (MPN) subtypes also carry typical chromosomal abnormalities, which however are not pathognomonic for a specific entity of MPN. According to the WHO classification the distinction between these entities is still based on the integration of cytological, histopathological and molecular findings. Progression of CML into accelerated and blastic phase is usually driven by additional chromosome abnormalities and <em>ABL1</em> kinase mutations<em>.</em> In the other MPN subtypes the additional mutations besides driver gene mutations in <em>JAK2</em>, <em>MPL</em> and <em>CALR</em> have a decisive impact on the propensity for progression. In addition, the sequence in which the driver mutations and risk conveying additional mutations have been acquired appears to play an important role. Here, we review cytogenetic and molecular changes in CML and MPN that should be evaluated during diagnosis and disease monitoring.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 2","pages":"Article 101552"},"PeriodicalIF":2.1,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000173/pdfft?md5=b5ad2665ab194c713fca304faf7b6626&pid=1-s2.0-S1521692624000173-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140545918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation 合作生物库 (CoBi)：促进未来造血细胞移植研究的捐献者和受者样本及数据

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-04-01 DOI: 10.1016/j.beha.2024.101551

Claudia Spielau , Carolin Bunzel , Stefan Abert , Henning Baldauf , Alexander H. Schmidt , Johannes Schetelig

{"title":"The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation","authors":"Claudia Spielau , Carolin Bunzel , Stefan Abert , Henning Baldauf , Alexander H. Schmidt , Johannes Schetelig","doi":"10.1016/j.beha.2024.101551","DOIUrl":"https://doi.org/10.1016/j.beha.2024.101551","url":null,"abstract":"<div><p>Biobanking provides benefit for future generations by facilitating medical research and subsequent translation and application of research findings. Long-term storage and research involving biological material and associated data necessitate the proper implementation of ethical and legal standards. A key principle includes recognizing informed consent as a crucial element for legitimizing the collection of biological material and data. Furthermore, any collected material and data must be employed exclusively for the research framework that aligns with the explicit consent provided by the participants. Last but not least, data privacy and security are essential in biobanking. This review elucidates chances and limitations of biobanking in the field of allogeneic hematopoietic cell transplantation. We discuss the practical implementation of the requirements, illustrated by the Collaborative Biobank, a collaborative research platform for research in blood cancer.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 2","pages":"Article 101551"},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000161/pdfft?md5=f96424adfe1772d4940807585220695e&pid=1-s2.0-S1521692624000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140545919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry 向全世界提供非亲属捐献者的造血干细胞产品：DKMS 捐赠者中心和 DKMS 登记处

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-03-01 DOI: 10.1016/j.beha.2024.101541

Alexander H. Schmidt , Jürgen Sauter , Johannes Schetelig , Elke Neujahr , Julia Pingel

{"title":"Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry","authors":"Alexander H. Schmidt , Jürgen Sauter , Johannes Schetelig , Elke Neujahr , Julia Pingel","doi":"10.1016/j.beha.2024.101541","DOIUrl":"10.1016/j.beha.2024.101541","url":null,"abstract":"<div><p>Allogeneic hematopoietic stem cell (HSC) transplantation is a curative therapy for many severe blood diseases. As many patients have no suitable family donor, large unrelated donor registries and donor centers have been established in many countries, along with an international system for the provision of unrelated donor HSC products. As an essential part of this system, DKMS operates donor centers in 7 countries with a total of 12.2 million donors and over 114,000 donations so far, and a multinational donor registry. In 2022, DKMS donors contributed 57.5% of all cross-border donations worldwide. In this review, we describe the international system for the provision of unrelated donor HSC products as well as tasks and responsibilities of donor registries and donor centers. We also discuss relevant aspects of DKMS donor centers, namely donor file composition, matching and donation probabilities and actual donations, and the unique multinational approach of the DKMS Registry.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 1","pages":"Article 101541"},"PeriodicalIF":2.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000069/pdfft?md5=bfe217d3a37e0a08be6bbce658f3e4af&pid=1-s2.0-S1521692624000069-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140019956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The landscape of cytogenetic and molecular genetic methods in diagnostics for hematologic neoplasia 血液肿瘤诊断中细胞遗传学和分子遗传学方法的前景

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-03-01 DOI: 10.1016/j.beha.2024.101539

Yvonne Lisa Behrens , Stefan Pietzsch , Željko Antić , Yanming Zhang , Anke K. Bergmann

引用次数: 0

Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479] 血液学研究中的终点选择和评估"[Best Pract Res Clin Haematol 36 (2023) 101479] 更正

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-02-23 DOI: 10.1016/j.beha.2024.101540

Ruta Brazauskas , Mary Eapen , Tao Wang

引用次数: 0

Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471] 血液和骨髓移植临床试验的设计与实施"[Best Pract Res Clin Haematol 36 (2023) 101471] 更正

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-02-02 DOI: 10.1016/j.beha.2024.101538

Michael J. Martens , Yan Gao , Aniko Szabo

引用次数: 0